Recent clinical studies of neoantigen cancer vaccines report similar observations, in which the peptide neoantigen cancer vaccines predominantly induced CD4+ T cells despite the peptides being selected based on MHC class I predictions5,6. This evidence concerns the gene CD4 and cancer.